Drug Trial Radar · NCT00146328
Rollover Trial Safety and Tolerability of Combination Tipranavir and Ritonavir Use in HIV 1 Infected Subjects
Last checked: Nov 20, 2026Latest source record: Mar 6, 2014 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
997
Actual
Start
Apr 2001
Primary completion
May 2008
Sponsor
- Lead sponsor
- Boehringer IngelheimBoehringer Ingelheim
- Sponsor type
- Industry
- First posted
- Sep 7, 2005
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The objective of this study is to determine the long term safety and tolerability of multiple oral doses of tipranavir (Aptivus) and ritonavir with a focus on the long term safety of the development dose (500 mg tipranavir/200 mg ritonavir BID) when administered with other antiretroviral medications.
Conditions
- HIV Infections
Interventions
TipranavirDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Patients With Division of Acquired Immunodeficiency Syndrome (DAIDS) Grade 3 or 4 - HaemoglobinTime frame: End of Trial (>288 weeks)
- Number of Patients With Division of Acquired Immunodeficiency Syndrome (DAIDS) Grade 3 or 4 - White Blood Cell ct.Time frame: End of Trial (>288 weeks)
- Number of Patients With Division of Acquired Immunodeficiency Syndrome (DAIDS) Grade 3 or 4 - PlateletsTime frame: End of Trial (>288 weeks)
- Number of Patients With Division of Acquired Immunodeficiency Syndrome (DAIDS) Grade 3 or 4 - Prothrombin TimeTime frame: End of Trial (>288 weeks)
- Number of Patients With Division of Acquired Immunodeficiency Syndrome (DAIDS) Grade 3 or 4 - SodiumTime frame: End of Trial (>288 weeks)
- Number of Patients With Division of Acquired Immunodeficiency Syndrome (DAIDS) Grade 3 or 4 - PotassiumTime frame: End of Trial (>288 weeks)
- Number of Patients With Division of Acquired Immunodeficiency Syndrome (DAIDS) Grade 3 or 4 - CalciumTime frame: End of Trial (>288 weeks)
- Number of Patients With Division of Acquired Immunodeficiency Syndrome (DAIDS) Grade 3 or 4 - PhosphateTime frame: End of Trial (>288 weeks)
- Number of Patients With Division of Acquired Immunodeficiency Syndrome (DAIDS) Grade 3 or 4 - Carbon DioxideTime frame: End of Trial (>288 weeks)
- Number of Patients With Division of Acquired Immunodeficiency Syndrome (DAIDS) Grade 3 or 4 - Aspartate Aminotransferase (AST/GOT,SGOT)Time frame: End of Trial (>288 weeks)
- Number of Patients With Division of Acquired Immunodeficiency Syndrome (DAIDS) Grade 3 or 4 - Alanine Aminotransferase (ALT/GPT,SGPT)Time frame: End of Trial (>288 weeks)
- Number of Patients With Division of Acquired Immunodeficiency Syndrome (DAIDS) Grade 3 or 4 - Alkaline PhosphataseTime frame: End of Trial (>288 weeks)
- Number of Patients With Division of Acquired Immunodeficiency Syndrome (DAIDS) Grade 3 or 4 - AmylaseTime frame: End of Trial (>288 weeks)
- Number of Patients With Division of Acquired Immunodeficiency Syndrome (DAIDS) Grade 3 or 4 - Creatine PhosphokinaseTime frame: End of Trial (>288 weeks)
- Number of Patients With Division of Acquired Immunodeficiency Syndrome (DAIDS) Grade 3 or 4 - LipaseTime frame: End of Trial (>288 weeks)
- Number of Patients With Division of Acquired Immunodeficiency Syndrome (DAIDS) Grade 3 or 4 - GlucoseTime frame: End of Trial (>288 weeks)
- Number of Patients With Division of Acquired Immunodeficiency Syndrome (DAIDS) Grade 3 or 4 - Cholesterol, TotalTime frame: End of Trial (>288 weeks)
- Number of Patients With Division of Acquired Immunodeficiency Syndrome (DAIDS) Grade 3 or 4 - CreatinineTime frame: End of Trial (>288 weeks)
- Number of Patients With Division of Acquired Immunodeficiency Syndrome (DAIDS) Grade 3 or 4 - Bilirubin, TotalTime frame: End of Trial (>288 weeks)
- Number of Patients With Division of Acquired Immunodeficiency Syndrome (DAIDS) Grade 3 or 4 - TriglyceridesTime frame: End of Trial (>288 weeks)
- Number of Patients With Division of Acquired Immunodeficiency Syndrome (DAIDS) Grade 3 or 4 - Uric AcidTime frame: End of Trial (>288 weeks)
- Number of Patients With Division of Acquired Immunodeficiency Syndrome (DAIDS) Grade 3 or 4 - AlbuminTime frame: End of Trial (>288 weeks)
- Number of Patients With Division of Acquired Immunodeficiency Syndrome (DAIDS) Grade 3 or 4 -Low-density Lipoprotein (LDL)Time frame: End of Trial (>288 weeks)
- Number of Patients With Adverse Events Leading to DeathTime frame: End of Trial (>288 weeks)
Locations
233 sites in 18 countries. Site status is shown where the registry gives one.
1182.17.39 MDS Pharma Services
Phoenix, Arizona
1182.17.75 Boehringer Ingelheim Investigational Site
Phoenix, Arizona
1182.17.89 Boehringer Ingelheim Investigational Site
Berkeley, California
1182.17.60 Boehringer Ingelheim Investigational Site
Fountain Valley, California
1182.17.106 Boehringer Ingelheim Investigational Site
Los Angeles, California
1182.17.15 Boehringer Ingelheim Investigational Site
Los Angeles, California
1182.17.40 Tower ID Medical
Los Angeles, California
1182.17.46 Boehringer Ingelheim Investigational Site
Los Angeles, California
1182.17.47 University of Southern California
Los Angeles, California
1182.17.73 Boehringer Ingelheim Investigational Site
Los Angeles, California
1182.17.114 Boehringer Ingelheim Investigational Site
San Diego, California
1182.17.128 Boehringer Ingelheim Investigational Site
San Diego, California
1182.17.37 Boehringer Ingelheim Investigational Site
San Francisco, California
1182.17.58 Boehringer Ingelheim Investigational Site
San Francisco, California
1182.17.96 Boehringer Ingelheim Investigational Site
San Francisco, California
1182.17.87 Boehringer Ingelheim Investigational Site
Norwalk, Connecticut
1182.17.112 Boehringer Ingelheim Investigational Site
Washington D.C., District of Columbia
1182.17.43 Boehringer Ingelheim Investigational Site
Washington D.C., District of Columbia
1182.17.65 Boehringer Ingelheim Investigational Site
Washington D.C., District of Columbia
1182.17.126 Boehringer Ingelheim Investigational Site
Fort Lauderdale, Florida
1182.17.8 Boehringer Ingelheim Investigational Site
Fort Myers, Florida
1182.17.131 Boehringer Ingelheim Investigational Site
Miami, Florida
1182.17.22 Boehringer Ingelheim Investigational Site
Miami, Florida
1182.17.64 Boehringer Ingelheim Investigational Site
Orlando, Florida
1182.17.129 Boehringer Ingelheim Investigational Site
Sarasota, Florida
1182.17.51 Boehringer Ingelheim Investigational Site
South Miami, Florida
1182.17.125 Boehringer Ingelheim Investigational Site
Tampa, Florida
1182.17.132 Boehringer Ingelheim Investigational Site
Tampa, Florida
1182.17.76 Boehringer Ingelheim Investigational Site
Tampa, Florida
1182.17.52 Boehringer Ingelheim Investigational Site
Vero Beach, Florida
1182.17.77 Boehringer Ingelheim Investigational Site
Atlanta, Georgia
1182.17.69 Boehringer Ingelheim Investigational Site
Macon, Georgia
1182.17.136 Boehringer Ingelheim Investigational Site
Chicago, Illinois
1182.17.70 Boehringer Ingelheim Investigational Site
Chicago, Illinois
1182.17.36 Boehringer Ingelheim Investigational Site
Evanston, Illinois
1182.17.1 Boehringer Ingelheim Investigational Site
Indianapolis, Indiana
1182.17.32 University of Kansas School of Medicine - Wichita
Wichita, Kansas
1182.17.102 Boehringer Ingelheim Investigational Site
Lexington, Kentucky
1182.17.21 Boehringer Ingelheim Investigational Site
Louisville, Kentucky
1182.17.30 Boehringer Ingelheim Investigational Site
Portland, Maine
Showing 40 of 233 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.